Table 3 Baseline characteristics according to blood culture results
Culture-negative n = 737 | Culture-positive n = 127 | Difference (95% CI) | |
|---|---|---|---|
Sex | |||
Female | 343(46.5) | 69(54.3) | 7.8(÷1.6–17.2) |
Male | 394(53.5) | 58(45.7) | |
Age, median (IQR) | 72.9(59.9–81.1) | 73.4(64.3–82.8) | 1.9(÷4.6–0.7) |
Charlson Comorbidity Index, n(%) | |||
0 | 197(26.7) | 37(29.1) | 2.4(÷6.1–10.9) |
1–2 | 373(50.6) | 54(42.5) | 8.1(÷1.2–17.4) |
3+ | 167(22.7) | 36(28.4) | 5.7(÷2.7–14.1) |
Severity of disease | |||
SOFA, median (IQR) | 2(0–3) | 2(1–4) | 0 |
SOFA > 3, n(%) | 109(14.8) | 37(29.1) | 14.3(6.0–22.6) |
SBP ≤ 90 mmHg, n(%)a | 25(3.4) | 14(11.0) | 7.6(2.0–13.2) |
RR, breath/min (IQR) | 21(18–25) | 22(19–29) | 0(0–3) |
HR, beats/min (IQR) | 98(88–111) | 106(93–118) | 7(3–11) |
Saturation, % (IQR) | 96(94–98) | 96(93–97) | 0 |
Temperature, oC (IQR)b | 37.9(37.0–38.6) | 38.4(37.7–39.1) | 0.5(0.3–0.7) |
GCS < 15, n(%) | 137(18.6) | 35(27.6) | 9.0(0.7–17.3) |
SIRS score, median (IQR) | 2(2–3) | 3(2–4) | 1(÷1–0) |
LOS, days, median (IQR) | 5.0(31–8.4) | 7.1(4.6–12.2) | 2.0(1.1–2.9) |
Laboratory variables, median (IQR) | |||
CRP | 92(34–161) | 141(68–249) | 44(19.1–68.0) |
WBC | 13(9.6–17.1) | 14.7(9.9–19.1) | 1.1(÷2.5-0.3) |
Focus of infection | |||
Pulmonary, n(%) | 463(62.8) | 67(52.8) | 10.0(0.6–19.4) |
Urinary tract, n(%) | 139(18.9) | 44(34.7) | 15.8(7.1–24.5) |
Abdominal, n(%) | 67(9.1) | 11(8.7) | 0.4(÷4.9–5.7) |
CNS, n(%) | 4(0.5) | 1(0.8) | 0.3(÷1.3–1.9) |
Skin, n(%) | 46(6.2) | 10(7.9) | 1.7(÷3.3–6.7) |
Endocarditis, n(%) | 3(0.4) | 1(0.8) | 0.4(÷1.2–2.0) |
I.V. AB treatment prior to BC, n(%) | 115(15.6) | 10(7.9) | 7.7(2.3–13.1) |
Time to first BC obtained, median hours (IQR) | 1.4(0.8–3.7) | 0.9(0.6–1.5) | 0.4(0.3–0.6) |
Number of BCs obtained, n(%) | |||
1 | 737(100) | 106(83.5) | 16.5(10.0–23.0) |
2 | 0 | 12(9.4) | |
3 | 0 | 7(5.5) | |
4 | 0 | 1(0.8) | |
5 | 0 | 1(0.8) | |
> 1 | 0 | 21(16.5) | 16.5(10.0–23.0) |